LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of January 9, 2026, LLY stock price declined to $1,063.56 with 2,390,997 million shares trading.

LLY has a beta of 0.40, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.02 to the broad based SPY ETF.

LLY has a market cap of $951.91 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $18 billion in Revenue and $7.02 earnings per share. This beat revenue expectation by $2 billion and exceeded earnings estimates by $1.06.

In the last 3 years, LLY traded as high as $1,133.95 and as low as $302.14.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, SPY, VUG.

LLY has outperformed the market in the last year with a return of +35.9%, while the SPY ETF gained +19.0%. In the last 3 month period, LLY beat the market returning +24.5%, while SPY returned +3.7%. However, in the most recent 2 weeks LLY has underperformed the stock market by returning -1.3%, while SPY returned +0.5%.

LLY support price is $1,064.76 and resistance is $1,105.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.